Stargardt Disease

Study of ALK-001 on the Progression of Stargardt Disease

Safety and Efficacy of Emixustat in Stargardt Disease

A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Disease

Phase 2/3 Study of ALK-001 in Geographic Atrophy

Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease

Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)

Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease

Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease

Phase 1 Safety Study of ALK-001 in Healthy Volunteers

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study